Real-world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: A multicentre retrospective study

被引:14
|
作者
Shragai, Tamir [1 ,2 ]
Magen, Hila [2 ,3 ]
Lavi, Noa [4 ,5 ]
Gatt, Moshe [6 ,7 ]
Trestman, Svetlana [1 ]
Zektser, Miri [8 ]
Ganzel, Chezi [7 ,9 ]
Jarchowsky, Osnat [2 ,10 ]
Berger, Tamar [2 ]
Tadmor, Tamar [5 ,11 ,12 ]
Leiba, Merav [13 ,14 ]
Hertzog-Tzarfaty, Katrin [15 ]
Horowitz, Netanel [4 ,5 ]
Shapira, Michael [16 ]
Varssano, David [2 ,17 ]
Berger, Yoav [18 ]
Frenkel, Shahar [7 ,19 ]
Krauthammer, Mark [2 ,17 ]
Avivi, Irit [1 ,2 ]
Luttwak, Efrat [1 ,2 ]
Cohen, Yael C. [1 ,2 ]
机构
[1] Tel Aviv Sourasky Med Ctr, Dept Haematol, Tel Aviv, Israel
[2] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel
[3] Chaim Sheba Med Ctr, Dept Haematol, Ramat Gan, Israel
[4] Rambam Hlth Care Campus, Dept Haematol, Haifa, Israel
[5] Technion Israel Inst Technol, Fac Med, Haifa, Israel
[6] Hadassah Med Ctr, Dept Haematol, Jerusalem, Israel
[7] Hebrew Univ Jerusalem, Fac Med, Jerusalem, Israel
[8] Soroka Univ, Dept Haematol, Med Ctr, Beer Sheva, Israel
[9] Shaare Zedek Med Ctr, Dept Haematol, Jerusalem, Israel
[10] Meir Med Ctr, Dept Haematol, Kefar Sava, Israel
[11] Rabin Med Ctr, Davidoff Canc Ctr, Inst Haematol, Petah Tiqwa, Israel
[12] Bnai Zion Med Ctr, Dept Haematol, Haifa, Israel
[13] Assuta Univ Hosp, Dept Haematol, Ashdod, Israel
[14] Ben Gurion Univ Negev, Fac Hlth Sci, Beer Sheva, Israel
[15] Shamir Med Ctr, Dept Haematol, Rishon Leziyyon, Israel
[16] Assuta Ramat HaHayal, Dept Haematol, Tel Aviv, Israel
[17] Tel Aviv Sourasky Med Ctr, Dept Ophthalmol, Tel Aviv, Israel
[18] Chaim Sheba Med Ctr, Dept Ophthalmol, Ramat Gan, Israel
[19] Hadassah Med Ctr, Dept Ophthalmol, Jerusalem, Israel
关键词
immunotherapy; multiple myeloma; myeloma therapy; T-CELL THERAPY; ANTIGEN; BCMA;
D O I
10.1111/bjh.18479
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Belantamab mafodotin, an immuno-conjugate targeting B-cell maturation antigen, showed single-agent activity in phase 1 and 2 studies, and was recently approved for heavily pretreated relapsed/refractory multiple myeloma (RRMM) patients. Real-world data and long-term follow-up are scarce. We conducted a multisite retrospective study aimed to assess safety and efficacy of belantamab mafodotin monotherapy administered via the GSK expanded access compassionate care programme. One-hundred and six RRMM patients were treated with belantamab mafodotin between July 2019 and March 2021. The median age was 69.4 years. Patients were heavily pretreated with a median of six (range 2-11) prior therapy lines. Major adverse effects included ocular toxicity (keratopathy 68.4%, grade >= 3: 40.5%; blurred vision 36.8%, grade >= 3: 6.3%), thrombocytopenia (27.4%, grade >= 3: 17.9%) and infections (11.3%, grade >= 3: 7.5%). Median follow-up time was 11.9 [95% confidence interval (CI) 10.0-13.8] months. Overall response rate was 45.5%. Median progression-free survival was 4.7 (95% CI 3.5-5.9) months in the entire cohort and 8.8 (95% CI 6.6-10.9) months among responders. Median overall survival was 14.5 (95% CI 9.5-19.6) months, and not reached for responders. To conclude, in a real-world setting, belantamab mafodotin monotherapy showed efficacy comparable with the prospective clinical trials, with a tolerable toxicity profile.
引用
收藏
页码:45 / 53
页数:9
相关论文
共 50 条
  • [1] Real-world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: a multi-center retrospective study
    Shragai, Tamir
    Magen, Hila
    Lavi, Noa
    Gatt, Moshe
    Trestman, Svetlana
    Zektser, Miri
    Ganzel, Chezi
    Jarchowsky, Osant
    Berger, Tamar
    Tadmor, Tamar
    Leiba, Merav
    Hertzog-Zarfaty, Katrin
    Horowitz, Netanel
    Shapira, Michael
    Varssano, David
    Berger, Yoav
    Frenkel, Shahar
    Krauthammer, Mark
    Avivi, Irit
    Luttwak, Efrat
    Cohen, Yael
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S98 - S98
  • [2] Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma, a Real-World Experience
    Hultcrantz, Malin
    Orozco, Jennifer
    Peterson, Tim J.
    Derkach, Andriy
    Hassoun, Hani
    Korde, Neha
    Lu, Sydney X.
    Mailankody, Sham
    Patel, Dhwani
    Shah, Urvi A.
    Tan, Carlyn
    Maclachlan, Kylee H.
    Chung, David J.
    Landau, Heather J.
    Shah, Gunjan L.
    Lahoud, Oscar B.
    Scordo, Michael
    Landgren, Ola
    Giralt, Sergio
    Lesokhin, Alexander
    [J]. BLOOD, 2021, 138
  • [3] Belantamab Mafodotin for relapsed/ refractory myeloma: A retrospective real-world, multicentre study from the UK and Ireland
    Watson, Edmund
    Djebbari, Faouzi
    Asher, Samir
    Walker, Mairi
    Saeed, Malahat
    Panitsas, Fotios
    Vallance, Grant
    Salhan, Beena
    Kyriakou, Charalampia
    Ramasamy, Karthik
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 71 - 72
  • [4] Retrospective, single-center, real-world experience of belantamab mafodotin in relapsed/refractory multiple myeloma
    Becnel, Melody
    Ferreri, Christopher
    Feng, Lei
    Richards, Tiffany
    Horowitz, Sandra
    Patel, Nimisha
    Gombos, Dan
    Razmandi, Azadeh
    Murga, Astrid
    Seif, Sherif
    Youssef, George
    Murphy, Kevin
    Kaufman, Gregory
    Weber, Donna
    Patel, Krina
    Thomas, Sheeba
    Manasanch, Elisabet
    Orlowski, Robert
    Lee, Hans
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S163 - S164
  • [5] Belantamab Mafodotin for Relapsed or Refractory Multiple Myeloma: A Real-World Observational Study Update
    Hultcrantz, Malin
    Kleinman, David
    Vij, Ravi
    Escalante, Fernando
    Delforge, Michel
    Kotowsky, Nirali
    Bitetti, Jacopo
    Boytsov, Natalie
    Camadoo-O'Byrne, Leena
    Happ, Lindsey Powers
    Rohman, Mujib
    Germain, Guillaume
    Duh, Mei Sheng
    Laliberte, Francois
    Mahendran, Malena
    Urosevic, Ana
    Lee, Hans
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S504 - S504
  • [6] Belantamab mafodotin for relapsed/refractory multiple myeloma: a real-world observational study update
    Hultcrantz, Malin
    Kleinman, David
    Vij, Ravi
    Escalante, Fernando
    Delforge, Michel
    Kotowsky, Nirali
    Bitetti, Jacopo
    Boytsov, Natalie
    Camadoo-O'Byrne, Leena
    Happ, Lindsey Powers
    Rohman, Mujib
    Germain, Guillaume
    Duh, Mei Sheng
    Laliberte, Francois
    Mahendran, Malena
    Urosevic, Ana
    Lee, Hans
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S185 - S186
  • [7] Retrospective, single-center, real-world experience of belantamab mafodotin in relapsed/refractory multiple myeloma.
    Becnel, Melody
    Ferreri, Christopher J.
    Feng, Lei
    Richards, Tiffany Ann
    Horowitz, Sandra B.
    Patel, Nimisha
    Gombos, Dan S.
    Razmandi, Azadeh
    Murga, Astrid
    Seif, Sherif
    Youssef, George
    Murphy, Kevin
    Kaufman, Gregory Peter
    Weber, Donna M.
    Patel, Krina K.
    Thomas, Sheeba K.
    Manasanch, Elisabet Esteve
    Orlowski, Robert Z.
    Lee, Hans C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [8] Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma, a Real-World Single Center Experience
    Hultcrantz, Malin
    Derkach, Andriy
    Hassoun, Hani
    Korde, Neha
    Maclachlan, Kylee H.
    Mailankody, Sham
    Patel, Dhwani
    Shah, Urvi A.
    Tan, Carlyn
    Akhlaghi, Theresia
    Hamadeh, Issam S.
    Chung, David J.
    Lahoud, Oscar B.
    Landau, Heather
    Scordo, Michael
    Shah, Gunjan L.
    Giralt, Sergio A.
    Lesokhin, Alexander M.
    Usmani, Saad
    [J]. BLOOD, 2022, 140 : 7246 - 7248
  • [9] Belantamab Mafodotin (Belamaf) for Relapsed/Refractory Multiple Myeloma (RRMM): A Real-World Observational Study
    Hultcrantz, Malin
    Kleinman, David
    Vij, Ravi
    Escalante, Fernando
    Kotowsky, Nirali
    Bitetti, Jacopo
    Mackay, Christine
    Boytsov, Natalie
    Camadoo-O'Byrne, Leena
    Germain, Guillaume
    Duh, Mei Sheng
    Laliberte, Francois
    Mahendran, Malena
    Urosevic, Ana
    Lee, Hans C.
    [J]. BLOOD, 2022, 140 : 10124 - 10126
  • [10] A real-world observational study of belantamab mafodotin (belamaf) as a treatment for relapsed/refractory multiple myeloma (RRMM)
    Cavo, Michele
    Delforge, Michel
    Dimopoulos, Meletios
    Escalante, Fernando
    Hultcrantz, Malin
    Kleinman, David
    Lee, Hans
    Vij, Ravi
    Kotowsky, Nirali
    Camadoo-O'Byrne, Leena
    Bitetti, Jacopo
    D'Estrube, Tim
    Fry, Mark
    Vossen, Carla
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S166 - S167